Bachmann’s pioneering DFMO research leads to FDA-approved lifesaving cancer drug
The U.S. Food and Drug Administration has approved a drug to treat neuroblastoma, an often-fatal pediatric cancer, based on pioneering research by College of Human Medicine professor André Bachmann. The FDA approved a tablet form of a drug called difluoromethylornithine, or DFMO (synonym eflornithine), developed in 1978 and later used to treat West African sleeping …